Our findings demonstrate that induction of MMR deficiency in neuroblastoma tumors can sensitize them to anti-CTLA4 treatment, which primarily relies on CD4+ T cells, but not anti-PD1 treatment, which mainly depends on CD8+ T cells.41 The gene discussed is CD4; the disease is neuroblastoma.